Negative Impact of Elevated DNA Fragmentation and Human Papillomavirus (HPV) Presence in Sperm on the Outcome of Intra-Uterine Insemination (IUI)

Depuydt, Christophe; Donders, Gilbert; Verstraete, Ludo; Beert, Johan; Salembier, Geert; Bosmans, Eugène; Dhont, Nathalie; Kerkhofs, Carmen; Ombelet, Willem

doi:10.3390/jcm10040717

Cited by 12 publications

(9 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sperm chromatin structure assay. The flow cytometric sperm chromatin structure assay was performed as previously described (13). The assay measures the percentage of spermatozoa with fragmented DNA (DNA fragmentation index, DFI) as well as the percentage of spermatozoa with high DNA stainability (HDS).…”

Section: Laboratory Proceduresmentioning

confidence: 99%

Sperm quality and absence of SARS-CoV-2 RNA in semen after COVID-19 infection: a prospective, observational study and validation of the SpermCOVID test

Donders

Bosmans²,

Reumers³

et al. 2022

Fertility and Sterility

Self Cite

View full text Add to dashboard Cite

Objective To study the contagiousness of sperm and its influence on fertility after recovery from COVID-19 infection. Design Prospective cohort study. Setting University medical center. Patient(s) One hundred twenty Belgian men who had recovered from proven COVID-19 infection. Intervention(s) No intervention was performed. Main outcome measure(s) Sermm quality was assessed using the World Health Organisation criteria. DNA damage to sperm cells was assessed by quantifying the DNA fragmentation index and the high density stainability. Finally antibodies against SARS-CoV2 spike-1 antigen, nuclear and S1-receptor binding domain were measured by Elisa and chemilumenscent microparticle immunoassays, repsectively. Result(s) SARS-CoV-2 RNA was not detected in semen during the period shortly after infection nor at a later time. Mean progressive motility was reduced in 60% of men tested shortly (<1 month) after COVID-19 infection, 37% of men tested 1 to 2 months after COVID-19 infection, and 28% of men tested >2 months after COVID-19 infection. Mean sperm count was reduced in 37% of men tested shortly (<1 month) after COVID-19 infection, 29% of men tested 1 to 2 months after COVID-19 infection, and 6% of men tested >2 months after COVID-19 infection. The severity of COVID-19 infection and the presence of fever were not correlated with sperm characteristics, but there were strong correlations between sperm abnormalities and the titers of SARS-CoV-2 IgG antibody against spike 1 and the receptor- binding domain of spike 1, but not against nucleotide, in serum. High levels of antisperm antibodies developed in three men (2.5%). Conclusion(s) Semen is not infectious with SARS-CoV-2 at 1 week or more after COVID-19 infection (mean, 53 days). However, couples with a desire for pregnancy should be warned that sperm quality after COVID-19 infection can be suboptimal. The estimated recovery time is 3 months, but further follow-up studies are under way to confirm this and to determine if permanent damage occurred in a minority of men.

show abstract

Section: Laboratory Proceduresmentioning

confidence: 99%

Sperm quality and absence of SARS-CoV-2 RNA in semen after COVID-19 infection: a prospective, observational study and validation of the SpermCOVID test

Donders

Bosmans²,

Reumers³

et al. 2022

Fertility and Sterility

Self Cite

View full text Add to dashboard Cite

show abstract

“…Pregnancy rate was reduced and the miscarriage rate was increased after HPV infection in both women and men [ 33 ]. Depuydt et al reported that the pregnancy rate with intra-uterine insemination (IUI) declined when the sperm DNA fragmentation index (DFI) exceeded 26%; and sperm samples containing HPV exhibited a significantly higher DFI compared with HPV-negative sperm samples (29.8% vs. 20.9%, respectively; p = 0.011) [ 37 ]. However, Hana et al recently reported that men with hrHPV-positive semen samples showed altered seminal parameters that included lower semen volume, sperm concentration, and total sperm count relative to men with HPV-negative samples; but there was no association between seminal hrHPV infection and pregnancy outcomes that included spontaneous abortion [ 36 ].…”

Section: Discussionmentioning

confidence: 99%

Prevalence of Human Papillomavirus Infection in the Female Partner of Infertile Couples Undergoing IVF/ICSI-ET and Subsequent Reproductive Outcomes

Wei

Wang

Cheng

et al. 2022

JCM

View full text Add to dashboard Cite

We investigated the prevalence of human papillomavirus (HPV) infection in the female partner of infertile couples and the reproductive outcomes after in vitro fertilization/intracytoplasmic sperm injection-embryo transfer (IVF/ICSI-ET). We conducted a retrospective analysis on 8117 women from infertile couples who underwent IVF/ICSI treatment and evaluated the prevalence of HPV infection in these women. The prevalence of HPV infection in the female partner of infertile couples was 9.2% (747/8117). These HPV-infected female patients undergoing ART were divided into high-risk HPV (hrHPV) (n = 130) and low-risk HPV (lrHPV) groups (n = 94), and non-infected women patients formed the negative group (n = 126). Of the 747 cases infected with HPV, 529 showed hrHPV infection (70.82%; primarily genotypes 16, 52, 53, 58, and 59); 175 exhibited lrHPV infection (23.43%; primarily genotypes 6, 43, 44, 55, 61, and 81); and 43 cases were co-infected with hrHPV and lrHPV (5.76%). Except for the Day-3 high-quality embryo rate, there were no differences in ovum maturation, fertilization, implantation, clinical pregnancy, live birth, or miscarriage rates between women infected with HPV and non-infected women (p > 0.05); however, we noted an increased miscarriage rate after logistic regression analyses (OR, 0.16; 95% CI, 0.03–0.84; p = 0.041). For single-male-factor-induced infertility in couples (smHPV), although we likewise observed no differences in ovum maturation, fertilization, or implantation rates (p > 0.05) between the smHPV group and the negative group, we discerned diminutions in the Day-3 high-quality embryo rate (46.01% vs. 70.04%, p = 0.013), clinical pregnancy rate (46.67% vs. 57.94%, p = 0.003), and live birth rate (33.33% vs. 46.83%, p = 0.027) as well as an augmented miscarriage rate (11.11% vs. 4.76%, p = 0.003), respectively. Logistic regression analyses indicated that smHPV was a risk factor for decreased clinical pregnancy rate (OR, 4.17; 95% CI, 2.31–7.53; p < 0.001) and live birth rate (OR, 1.83; 95% CI, 0.81–2.14; p = 0.045) and elevated miscarriage rate (OR, 6.83; 95% CI, 2.22–21.00; p = 0.001). HPV infection in women was associated with increased miscarriage rate, and single-male-factor infertility influenced reproductive outcomes in couples undergoing IVF/ICSI treatment. Both were potentially due to HPV infection in the couple.

show abstract

“…Christophe et al reported that the pregnancy rate with intra-uterine insemination (IUI) declined when the sperm DNA fragmentation index (DFI) exceeded 26%; and sperm samples containing HPV exhibited a signi cantly higher DFI compared with HPV-negative sperm samples (29.8% vs. 20.9%, respectively; p = 0.011) [37]. However, Hana et al recently reported that men with hrHPV-positive semen samples showed altered seminal parameters that included lower semen volume, sperm concentration, and total sperm count relative to men with HPV-negative samples; but there was no association between seminal hrHPV infection and pregnancy outcomes that included spontaneous abortion [36].…”

Section: Discussionmentioning

confidence: 99%

Prevalence of human papillomavirus infection in the female partner of infertile couples undergoing IVF/ICSI-ET and subsequent reproductive outcomes

Wei

Cheng

Chang

et al. 2022

Preprint

View full text Add to dashboard Cite

Background Whether human papillomavirus (HPV) infection alters the efforts of assisted reproductive technology (ART) and whether it is associated with reproductive outcomes are controversial. In this study, we investigated the prevalence of human papillomavirus infection in the female partner of infertile couples and the reproductive outcomes after in vitro fertilization/intracytoplasmic sperm injection-embryo transfer (IVF/ICSI-ET). Methods We conducted a retrospective analysis on 8117 women from infertile couples who underwent IVF/ICSI treatment at Tangdu Hospital Reproductive Medical Center in 2020 and evaluated the prevalence of HPV infection in these women. These HPV-infected female patients undergoing ART were divided into high-risk HPV (hr-HPV) (n = 130) and low-risk HPV (lr-HPV) groups (n = 94), and non-infected women patients formed the negative group (n = 126). All patients underwent a fresh-cycle embryo transfer or a frozen-embryo cycle transfer after a controlled ovarian hyperstimulation cycle. We analyzed subsequent embryonic development and reproductive outcomes. Results Of the 8117 cases, 747 were infected with HPV (9.2%): 529 showed hr-HPV infection (70.82%; principally genotypes 16, 52, 53, 58, and 59); 175 exhibited lr-HPV infection (23.43%; primarily genotypes 6, 43, 44, 55, 61, and 81); and 43 cases were co-infected with hr-HPV and lr-HPV (5.76%). Except for the Day-3 good-quality embryo rate, there were no differences in ovum maturation, fertilization, implantation, clinical pregnancy, live-birth, or miscarriage rates between women infected with HPV and non-infected women (p > 0.05); however, we noted a reduced miscarriage rate after logistic regression analyses (OR, 0.16; 95% CI, 0.03–0.84; p = 0.041). For single-male-factor-induced infertility in couples (sm-HPV), although we likewise observed no differences in ovum maturation, fertilization, or implantation rates (p > 0.05) between the sm-HPV group and the negative group, we discerned diminutions in the Day-3 good-quality embryo rate (46.01% vs. 70.04%, p = 0.013), clinical pregnancy rate (46.67% vs. 57.94%, P = 0.003), and live-birth rate (33.33% vs. 46.83%, p = 0.027); and an augmented miscarriage rate (11.11% vs. 4.76%, p = 0.003), respectively. Logistic regression analyses indicated that sm-HPV was a risk factor for decreased clinical pregnancy rate (OR, 4.17; 95% CI, 2.31–7.53; p < 0.001) and live-birth rate (OR, 1.83; 95% CI, 0.81–2.14; p = 0.045), and elevated miscarriage rate (OR, 6.83; 95% CI, 2.22–21.00 p = 0.001). Conclusions High-risk HPV infections are predominant in the female partners of infertile couples. HPV infection in these women was associated with decreased miscarriage rate, and single-male-factor infertility influenced reproductive outcomes in couples undergoing IVF/ICSI treatment—both potentially due to HPV infection in the couple.

show abstract

Negative Impact of Elevated DNA Fragmentation and Human Papillomavirus (HPV) Presence in Sperm on the Outcome of Intra-Uterine Insemination (IUI)

Cited by 12 publications

References 57 publications

Sperm quality and absence of SARS-CoV-2 RNA in semen after COVID-19 infection: a prospective, observational study and validation of the SpermCOVID test

Sperm quality and absence of SARS-CoV-2 RNA in semen after COVID-19 infection: a prospective, observational study and validation of the SpermCOVID test

Prevalence of Human Papillomavirus Infection in the Female Partner of Infertile Couples Undergoing IVF/ICSI-ET and Subsequent Reproductive Outcomes

Prevalence of human papillomavirus infection in the female partner of infertile couples undergoing IVF/ICSI-ET and subsequent reproductive outcomes

Contact Info

Product

Resources

About